Bristol-Myers Squibb (BMY)
$67.46 0.02 (0.04%)
11:56 EST BMY Stock Quote Delayed 15 Minutes
Previous Close $67.43
Market Cap 110.26B
PE Ratio 118.34
Volume (Avg. Vol.) 4.26M
Day's Range 67.25 - 68.34
52-Week Range 42.48 - 67.62
Dividend & Yield 1.60 (2.37%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign?
Options trading was hot in Bristol-Myers Squibb, Cronos and Canopy Growth stock on Tuesday. Here’s what the data suggests moving forward.
Goldman Sachs analysts came out with three conviction buys on Monday. Here's what else happened in the stock market today.
Options trading was buzzing in Bristol-Myers Squibb, Shopify and Walmart stock on Wednesday. Here are the metrics that matter moving forward.
Roku, Bristol-Myers Squibb, Bank of America and Gogo were our top stock trades for Tuesday. Here's a look at the charts.
Billionaire-owned companies perform twice as well as others. Turns out the world's wealthiest and most powerful make for good investors.
Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.
A weak start for stocks in October will create good entry points for growth investors. Here are seven of the best prospects to look at.
There's a lot in the news this week, from talks of an impeachment to a potential trade war resolution. Buy these healthcare stocks to benefit.
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
Low P/E stocks often are cheap stocks for a reason. But these 10 stocks to buy have not just reasonable valuations, but strong bull cases.
Roku, Adobe Systems, Beyond Meat and Bristol-Myers Squibb are our top stock trades. Read on to see what the charts say.
These 10 stocks don't quite qualify as "set it and forget it" plays. All have some degree of risk. But the risks seem worth taking for the potential rewards, which include near-term income, longer-term growth, and potential capital appreciation.
Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
Navellier RatingsPowered by Portfolio Grader